Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PKLR | P30613 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.37 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880943 | 0.88 | MALT1 (0.45) | MALT1OPRD1KCNH2ALDH1A1LMNA | |
| SCHEMBL4876701 | 0.87 | ALDH1A1 (0.50) | ALDH1A1LMNAHPGD | |
| SCHEMBL4876766 | 0.86 | KMT2A (0.46) | MALT1OPRD1KCNH2ALDH1A1LMNA | |
| SCHEMBL4876644 | 0.84 | SOAT1 (0.51) | SOAT1 | |
| SCHEMBL4880637 | 0.84 | MALT1 (0.41) | MALT1OPRD1KCNH2PKLRALDH1A1 | |
| Hydrochloric Acid SCHEMBL4880951 | 0.83 | SOAT1 (0.51) | SOAT1 | |
| SCHEMBL4881113 | 0.83 | SOAT1 (0.50) | SOAT1 | |
| SCHEMBL4880541 | 0.81 | SOAT1 (0.48) | OPRD1ALDH1A1SOAT1 | |
| SCHEMBL4876387 | 0.79 | SOAT1 (0.47) | SOAT1 | |
| SCHEMBL4880472 | 0.76 | STS (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | SCN10A 1115/4885MALT1 2298/4885OPRD1 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.